Lataa...
Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway
Diabetic nephropathy (DN) is the leading cause of end-stage failure of the kidney, but the efficacy of current strategies available for the prevention of DN remains unsatisfactory. The purpose of this study was to assess whether sitagliptin (SIT) has therapeutic potential for prevention of DN and to...
Tallennettuna:
| Julkaisussa: | Int J Mol Med |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
D.A. Spandidos
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846674/ https://ncbi.nlm.nih.gov/pubmed/29484381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijmm.2018.3504 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|